PL EN


Preferences help
enabled [disable] Abstract
Number of results
2013 | 13 | 1 | 24–30
Article title

Aktualne poglądy na temat roli witaminy D w patogenezie stwardnienia rozsianego

Content
Title variants
EN
The current concepts on the role of vitamin D in pathogenesis of multiple sclerosis
Languages of publication
PL
Abstracts
EN
Vitamin D is commonly known for its role in calcium-phosphate metabolism but there is growing amount of data showing its pleiotropic actions. Positive correlation between vitamin D deficiency and the prevalence of autoimmune diseases including multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, etc. has been observed. Vitamin D receptors have been found in spectrum of tissues and organs, including bones, muscles, reproductive organs, heart, brain, and within the immune system. Widely investigated immunomodulatory action of vitamin D affects both innate and adaptive immunity by suppressing T cell proliferation and cytotoxity, promoting regulatory T cells differentiation and modulating macrophage and dendritic cell functions. Multiple sclerosis (MS) is an autoimmune disease of the central nervous system caused by complex and predominantly unknown interactions of genetic susceptibility and environmental factors. Epidemiological studies show that the sun exposure and corresponding vitamin D level are important factors that can explain geographical distribution of MS. Some preliminary observations suggest that vitamin D supplementation not only reduces the risk of developing MS but also modulates disease course and reduces relapses rate among patients with relapsing-remitting MS. Further studies and clinical trials are required to confirm the role of vitamin D in MS pathogenesis.
PL
Witamina D jest powszechnie znana ze swojej roli w gospodarce wapniowo-fosforanowej, ale wzrastająca ilość danych wskazuje na jej działania plejotropowe. Zaobserwowano pozytywną korelację między niedoborem witaminy D a występowaniem chorób autoimmunologicznych, w tym stwardnienia rozsianego, reumatoidalnego zapalenia stawów, tocznia rumieniowatego układowego itp. Receptory witaminy D są obecne w szeregu tkanek i narządów, w tym w kościach, mięśniach, narządach rozrodczych, sercu, mózgu oraz w obrębie układu odpornościowego. Coraz lepiej poznawane działanie immunomodulujące witaminy D obejmuje wpływ zarówno na mechanizmy odporności wrodzonej, jak i adaptacyjnej, poprzez hamowanie proliferacji i cytotoksyczności limfocytów T, promowanie różnicowania limfocytów T regulatorowych oraz modulowanie działania makrofagów i komórek dendrytycznych. Stwardnienie rozsiane (łac. sclerosis multiplex, SM) jest chorobą autoimmunologiczną ośrodkowego układu nerwowego spowodowaną przez skomplikowane i w dużej mierze nieznane interakcje między predyspozycjami genetycznymi i czynnikami środowiskowymi. Badania epidemiologiczne wskazują, że ekspozycja na promieniowanie słoneczne i związany z nią poziom witaminy D są ważnymi czynnikami mogącymi wyjaśniać zróżnicowanie geograficzne częstości zachorowań na SM. Wyniki niektórych wstępnych obserwacji sugerują, że suplementacja witaminy D może zmniejszać ryzyko zachorowania na SM oraz modulować przebieg choroby i zmniejszać częstość jej nawrotów u pacjentów z rzutowo-remisyjną postacią SM. Wyniki te skłoniły do podjęcia prób włączenia witaminy D jako składnika wspomagającego terapię SM. Obserwacje te wymagają dalszego potwierdzenia i badań klinicznych.
Discipline
Year
Volume
13
Issue
1
Pages
24–30
Physical description
References
  • 1. Pierrot-Deseilligny C., Souberbielle J.C.: Is hypovitaminosis D one of the environmental risk factors for multiple sclerosis? Brain 2010; 133: 1869–1888.
  • 2. Fernandes de Abreu D.A., Eyles D., Féron F.: Vitamin D, a neuro-immunomodulator: Implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology 2009; 34 supl. 1: S265–S277.
  • 3. Holick M.F.: Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am. J. Clin. Nutr. 2004; 80 (supl.): 1678S–1688S.
  • 4. Pérez-López F.R., Brincat M., Erel C.T. i wsp.: EMAS position statement: vitamin D and postmenopausal health. Maturitas 2012; 71: 83–88.
  • 5. Muscogiuri G., Sorice G.P., Ajjan R. i wsp.: Can vitamin D deficiency cause diabetes and cardiovascular diseases? Present evidence and future perspectives. Nutr. Metab. Cardiovasc. Dis. 2012; 22: 81–87.
  • 6. Grant W.B.: Epidemiology of disease risks in relation to vitamin D insufficiency. Prog. Biophys. Mol. Biol. 2006; 92: 65–79.
  • 7. van Belle T.L., Gysemans C., Mathieu C.: Vitamin D in autoimmune, infectious and allergic diseases: a vital player? Best Pract. Res. Clin. Endocrinol. Metab. 2011; 25: 617–632.
  • 8. Holick M.F.: The vitamin D deficiency pandemic and consequences for nonskeletal health: mechanisms of action. Mol. Aspects Med. 2008; 29: 361–368.
  • 9. Cantorna M.T.: Vitamin D and multiple sclerosis: an update. Nutr. Rev. 2008; 66 (supl. 2): S135–S138.
  • 10. Bouvard B., Annweiler C., Sallé A. i wsp.: Extraskeletal effects of vitamin D: facts, uncertainties, and controversies. Joint Bone Spine 2011; 78: 10–16.
  • 11. Souberbielle J.C., Friedlander G., Kahan A., Cormier C.: Evaluating vitamin D status. Implications for preventing and managing osteoporosis and other chronic diseases. Joint Bone Spine 2006; 73: 249–253.
  • 12. Holick M.F.: Vitamin D deficiency. N. Engl. J. Med. 2007; 357: 266–281.
  • 13. Hanwell H.E., Banwell B.: Assessment of evidence for a protective role of vitamin D in multiple sclerosis. Biochim. Biophys. Acta 2011; 1812: 202–212.
  • 14. Wang T.T., Tavera-Mendoza L.E., Laperriere D. i wsp.: Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol. Endocrinol. 2005; 19: 2685–2695.
  • 15. Berlanga-Taylor A.J., Disanto G., Ebers G.C., Ramagopalan S.V.: Vitamin D-gene interactions in multiple sclerosis. J. Neurol. Sci. 2011; 311: 32–36.
  • 16. Norman A.W.: Vitamin D receptor: new assignments for an already busy receptor. Endocrinology 2006; 147: 5542–5548.
  • 17. Chaudhuri A.: Why we should offer routine vitamin D supplementation in pregnancy and childhood to prevent multiple sclerosis. Med. Hypotheses 2005; 64: 608–618.
  • 18. Ascherio A., Munger K.L., Simon K.C.: Vitamin D and multiple sclerosis. Lancet Neurol. 2010; 9: 599–612.
  • 19. Glade M.J.: A 21st century evaluation of the safety of oral vitamin D. Nutrition 2012; 28: 344–356.
  • 20. Marcinowska-Suchowierska E., Walicka M., Tałałaj M. i wsp.: Suplementacja witaminy D u ludzi dorosłych – wytyczne. Postępy Nauk Medycznych 2010; 2: 160–166.
  • 21. Baeke F., Takiishi T., Korf H. i wsp.: Vitamin D: modulator of the immune system. Curr. Opin. Pharmacol. 2010; 10: 482–496.
  • 22. Borges M.C., Martini L.A., Rogero M.M.: Current perspectives on vitamin D, immune system, and chronic diseases. Nutrition 2011; 27: 399–404.
  • 23. Cippitelli M., Santoni A.: Vitamin D3: a transcriptional modulator of the interferon-gamma gene. Eur. J. Immunol. 1998; 28: 3017–3030.
  • 24. Zhu J., Yamane H., Cote-Sierra J. i wsp.: GATA-3 promotes Th2 responses through three different mechanisms: induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors. Cell Res. 2006; 16: 3–10.
  • 25. Tang J., Zhou R., Luger D. i wsp.: Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J. Immunol. 2009; 182: 4624–4632.
  • 26. Zhang H.L., Wu J.: Role of vitamin D in immune responses and autoimmune diseases, with emphasis on its role in multiple sclerosis. Neurosci. Bull. 2010; 26: 445–454.
  • 27. Smolders J., Menheere P., Thewissen M. i wsp.: Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1,25-dihydroxyvita-min D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosis. J. Steroid Biochem. Mol. Biol. 2010; 121: 243–246.
  • 28. Burton J.M., Kimball S., Vieth R. i wsp.: A phase I/II doseescalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010; 74: 1852–1859.
  • 29. Harms L.R., Burne T.H.J., Eyles D.W., McGrath J.J.: Vitamin D and the brain. Best Pract. Res. Clin. Endocrinol. Metab. 2011; 25: 657–669.
  • 30. Balabanova S., Richter H.P., Antoniadis G.: 25-Hydroxyvitamin D, 24, 25-dihydroxyvitamin D and 1,25-dihydroxyvitamin D in human cerebrospinal fluid. Klin. Wochenschr. 1984; 62: 1086–1090.
  • 31. Eyles D.W., Smith S., Kinobe R. i wsp.: Distribution of the vitamin D receptor and 1α-hydroxylase in human brain. J. Chem. Neuroanat. 2005; 29: 21–30.
  • 32. Naveilhan P., Neveu I., Baudet C. i wsp.: Expression of 25(OH) vitamin D3 24-hydroxylase gene in glial-cells. Neuroreport 1993; 5: 255–257.
  • 33. Brewer L.D., Thibault V., Chen K.C. i wsp.: Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. J. Neurosci. 2001; 21: 98–108.
  • 34. Wion D., MacGrogan D., Neveu I. i wsp.: 1,25-Dihydroxyvitamin D3 is a potent inducer of nerve growth factor synthesis. J. Neurosci. Res. 1991; 28: 110–114.
  • 35. Neveu I., Naveilhan P., Jehan F. i wsp.: 1,25-dihydroxyvitamin D3 regulates the synthesis of nerve growth factor in primary cultures of glial cells. Brain Res. Mol. Brain Res. 1994; 24: 70–76.
  • 36. Taniura H., Ito M., Sanada N. i wsp.: Chronic vitamin D3 treatment protects against neurotoxicity by glutamate in association with upregulation of vitamin D receptor mRNA expression in cultured rat cortical neurons. J. Neurosci. Res. 2006; 83: 1179–1189.
  • 37. Brown J., Bianco J.I., McGrath J.J., Eyles D.W.: 1,25-dihydroxyvitamin D3 induces nerve growth factor, promotes neuriteoutgrowth and inhibits mitosis in embryonic rat hippocampal neurons. Neurosci. Lett. 2003; 343: 139–143.
  • 38. Hernán M.A., Olek M.J., Ascherio A.: Geographic variation of MS incidence in two prospective studies of US women. Neurology 1999; 53: 1711–1718.
  • 39. Hayes C.E., Cantorna M.T., DeLuca H.F.: Vitamin D and multiple sclerosis. Proc. Soc. Exp. Biol. Med. 1997; 216: 21–27.
  • 40. Kampman M.T., Brustad M.: Vitamin D: a candidate for the environmental effect in multiple sclerosis – observations from Norway. Neuroepidemiology 2008; 30: 140–146.
  • 41. Islam T., Gauderman W.J., Cozen W., Mack T.M.: Childhood sun exposure influences risk of multiple sclerosis in monozygotic twins. Neurology 2007; 69: 381–388.
  • 42. Kampman M.T., Wilsgaard T., Mellgren S.I.: Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J. Neurol. 2007; 254: 471–477.
  • 43. van der Mei I.A., Ponsonby A.L., Dwyer T. i wsp.: Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J. Neurol. 2007; 254: 581–590.
  • 44. van der Mei I.A., Ponsonby A.L., Dwyer T. i wsp.: Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ 2003; 327: 316–321.
  • 45. Kurtzke J.F., Delasnerie-Lauprêtre N., Wallin M.T.: Multiple sclerosis in North African migrants to France. Acta Neurol. Scand. 1998; 98: 302–309.
  • 46. Elian M., Nightingale S., Dean G.: Multiple sclerosis among United Kingdom-born children of immigrants from the Indian subcontinent, Africa and the West Indies. J. Neurol. Neurosurg. Psychiatry 1990; 53: 906–911.
  • 47. Munger K.L., Zhang S.M., O’Reilly E. i wsp.: Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62: 60–65.
  • 48. Munger K.L., Levin L.I., Hollis B.W. i wsp.: Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296: 2832–2838.
  • 49. Soilu-Hänninen M., Airas L., Mononen I. i wsp.: 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult. Scler. 2005; 11: 266–271.
  • 50. Correale J., Ysrraelit M.C., Gaitán M.I.: Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain 2009; 132: 1146–1160.
  • 51. Simpson S. Jr, Taylor B., Blizzard L. i wsp.: Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann. Neurol. 2010; 68: 193–203.
  • 52. Mahon B.D, Gordon S.A., Cruz J. i wsp.: Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J. Neuroimmunol. 2003; 134: 128–132.
  • 53. Kimball S.M., Ursell M.R., O’Connor P., Vieth R.: Safety of vitamin D3 in adults with multiple sclerosis. Am. J. Clin. Nutr. 2007; 86: 645–651.
  • 54. Bischoff-Ferrari H.A., Giovannucci E., Willett W.C. i wsp.: Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am. J. Clin. Nutr. 2006; 84: 18–28.
  • 55. Kimball S.M., Burton J.M., O’Connor P.G. i wsp.: Urinary calcium response to high dose vitamin D3 with calcium supplementation in patients with multiple sclerosis. Clin. Biochem. 2011; 44: 930–932.
  • 56. Vieth R.: Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am. J. Clin. Nutr. 1999; 69: 842–856.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-479c7009-b995-4888-8ace-959f840e6265
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.